This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Market Perform from Outperform ...

Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

In this week’s edition of InnovationRx, we look at the impact of Trump’s proposed budget cuts on biomedical research and ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

The health industry witnesses significant developments as Hims & Hers acquires UK startup Zava, Sanofi plans a $9.5 billion ...

Braskem S.A. (São Paulo, Brazil) and Ardent Process Technologies (New Castle, Del.) announced the successful completion of ...

This happened after Sanofi announced plans to buy the company for $9.1 billion in stock value and up to $9.5 billion in ...